Emerson 10-K: FY26 Sales $19.0B, Adjusted EPS $6.59; FY27 Guidance ~$7.25
EMR sits 38% above its 52-week low of $122.635.
Summary
Emerson's FY2026 10-K confirms $19.0B of sales (+5%) and $6.59 adjusted EPS (+10%), and sets FY2027 guidance at ~$7.25 adjusted EPS with $3.8-3.9B of free cash flow.
Key Events · Earnings and Guidance · EMR
-
FY26 Sales $19.0B, Adjusted EPS $6.59
Net sales rose 5% to $18,982M from $18,016M; adjusted diluted EPS from continuing operations rose 10% to $6.59 from $6.01, and GAAP diluted EPS was $4.79.
-
FY27 Guidance: ~$7.25 Adjusted EPS
Management guides fiscal 2027 sales up approximately 5%, diluted EPS of approximately $5.70 and adjusted EPS of approximately $7.25, with operating cash flow of $4.3-4.4B and free cash flow of $3.8-3.9B.
-
Backlog Climbs to $9.6B
Consolidated backlog was $9,593M at September 30, 2026 versus $8,629M a year earlier, with about 70% expected to convert to revenue within 12 months.
-
Debt Cut, Coverage at 9.0x
Total debt fell to $12,175M from $13,116M, taking the debt-to-total-capital ratio to 37.0% from 39.3%; the interest coverage ratio improved to 9.0x from 8.5x.
Analysis · EMR · Manufacturing
The annual report locks in the numbers the market already saw in the November 4 pre-announcement, but it is the first audited, full-year document and the first place the complete FY2027 outlook appears in filing form: sales up ~5%, adjusted EPS ~$7.25, and $3.8-3.9B of free cash flow. A clean audit is confirmed as well (KPMG unqualified, no material weakness, no going-concern language), alongside a stronger balance sheet, with total debt down to $12.2B from $13.1B and interest coverage at 9.0x. Note that the pension mark-to-market accounting change adopted this year is a presentation shift, not a cash event. For holders, the takeaway is that the transformation story — software-heavy mix, $9.6B backlog, 53.4% gross margin — is now the audited baseline against which FY2027 will be measured.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EMR was trading at $169.52 on NYSE in the Manufacturing sector, with a market capitalization of approximately $94.6B. The 52-week trading range was $122.64 to $172.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.